Increased motion and travel, rather than stable docking, characterize the last moments before secretory granule fusion.
The state of secretory granules immediately before fusion with the plasma membrane is unknown, although the granules are generally assumed to be stably bound (docked). We had previously developed methods using total internal reflection fluorescence microscopy and image analysis to determine the position of chromaffin granules immediately adjacent to the plasma membrane with high precision, often to within approximately 10 nm, or <5% of the granule diameter (300 nm). These distances are of the dimensions of large proteins and are comparable with the unitary step sizes of molecular motors. Here we demonstrate with quantitative measures of granule travel in the plane parallel to the plasma membrane that secretory granules change position within several hundred milliseconds of nicotinic agonist-induced fusion. Furthermore, just before fusion, granules frequently move to areas that they have rarely visited. The movement of granules to new areas is most evident for granules that fuse later during the stimulus. The movement may increase the probability of productive interactions of the granule with the plasma membrane or may reflect the pull of molecular interactions between the granule and the plasma membrane that are part of the fusion process. Thus, instead of being stably docked before exocytosis, granules undergo molecular-scale motions and travel immediately preceding the fusion event.
Degtyar
Vadim E
VE
Department of Pharmacology, University of Michigan, Ann Arbor, MI 48104-0632, USA.
Allersma
Miriam W
MW
Axelrod
Daniel
D
Holz
Ronald W
RW
D000313:Adrenal Medulla / Q000502:physiology; D000818:Animals; D002417:Cattle; D002462:Cell Membrane / Q000502:physiology*; D007700:Kinetics; D008561:Membrane Fusion / Q000187:drug effects / Q000502:physiology; D009043:Motor Activity / Q000502:physiology*; D018722:Nicotinic Agonists / Q000494:pharmacology; D022142:Secretory Vesicles / Q000502:physiology*
D018722:Nicotinic Agonists